Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 11, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled

NEW YORK, Oct. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
October 07, 2019 08:04 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform

NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that...
October 02, 2019 06:45 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis (NEALS) 18th Annual Meeting

NEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
September 27, 2019 04:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development

NEW YORK, Sept. 27, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
September 09, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that...
September 06, 2019 01:50 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress

NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
August 13, 2019 07:30 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update

Conference Call and Webcast Today at 8:00 a.m. Eastern Time Highlights Include: Special High-level FDA Meeting, Continued Progress in NurOwn® ALS Phase 3 Trialand Progressive MS Phase 2 Trial,...
August 05, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update

NEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
July 02, 2019 08:15 ET | Source: BrainStorm Cell Therapeutics Inc.

Third Clinical Site Initiated for BrainStorm Cell Therapeutic’s Phase 2 Progressive MS Study

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
May 31, 2019 01:00 ET | Source: BrainStorm Cell Therapeutics Inc.

BrainStorm Presents Poster at Consortium of Multiple Sclerosis Centers (CMSC) 33rd Annual Meeting

NEW YORK and SEATTLE, May 31, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...